In line with the Company’s Fix, Fund, Propel
approach, Dana J Moss, JD joins Navidea’s Board, adding depth in
legal advice, strategic business, life sciences and technology in
support of stated strategy to advance innovative technology to
market. Separately, Amit Bhalla steps down from Board.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced Dana J Moss, JD has joined the Company’s Board of
Directors, adding depth in legal advice, strategic business, life
sciences and technology in line with Navidea’s stated objectives
and its Fix, Fund, Propel approach to advancing innovative
technology to market. Separately, Amit Bhalla has stepped down from
the Company’s Board.
Experienced Legal Professional, Focused Life Sciences and
Technology Expertise
Dana J Moss, JD joins Navidea’s Board of Directors with
demonstrated leadership and legal expertise within innovative
organizations focused on life sciences and technology driven
products. Moss’s career and expertise within both private and
public entities bolsters the Board’s ability to guide business
strategy, mitigate risks and deliver stockholder value.
“Dana Moss’s addition allows Navidea to level-up expertise in
several important areas within the Board,” said Dr. Jason Myers,
Owner and Founder of G2G Ventures. “She is a demonstrated expert
and professional in the truest sense, with a career that includes
strategy, finance, mergers and acquisitions, governance,
litigation, and risk mitigation. Dana understands where we are and
where we are heading, and has the skills and experience to guide
Navidea’s technology and assets to the forefront.”
Dana J Moss previously served as the Chief Legal Officer and
Corporate Secretary at Sequencing Health, Inc., where she was
responsible for all legal, regulatory, compliance, and intellectual
property matters, led strategy related to fundraising, mergers and
acquisitions, and oversaw finance, corporate governance and human
resources functions. Her previous experience includes serving as
General Counsel, Corporate Secretary at Genapsys, Inc., as a
Partner at Cooley LLP with a focus on Commercial Litigation,
Program Manager at Mantech International Corporation, and as a
Special Agent and Operations Officer of the U.S. Air Force Office
of Special Investigations. Ms. Moss earned a Bachelor of Science at
the United Air Force Academy, where she was a distinguished
graduate, a Master of Arts in Philosophy at the University of Texas
at Austin as a USAFA Graduate School Scholarship recipient, and a
Juris Doctorate at the University of Maryland Francis King Carey
School of Law, where she graduated cum laude. Dana is a 2021 Fellow
of the Leadership Council on Legal Diversity and has served on the
organizing Board of MissionLink, a nonprofit membership
organization for C-level executives of high growth technology
companies.
Separately, Amit Bhalla has decided to step down from the Board
to focus on other business interests.
“We thank Amit Bhalla for his many contributions during his time
with the Board,” said John K. Scott, Jr, Navidea’s Vice Chair of
the Board. “Amit’s strategic guidance and expertise within the
emerging medical technology space have helped us press our business
forward, and we wish him the very best as we continue developing
processes and growth strategies led by Navidea’s team of experts
and our experienced partners in G2G Ventures.”
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, visit www.navidea.com.
About G2G Ventures
G2G Ventures is a Colorado-based private equity firm focused on
empowering organizations to reach their full potential through
investment and consulting services. Specializing in creating
long-term partnerships with trusted investors and established
businesses, G2G Ventures draws on strong internal balance sheet
liquidity, augmented by trusted investor capital, to craft bespoke
capital solutions which include private equity investment, venture
capital participation, and mezzanine debt options. Beyond financial
investment, G2G Ventures provides accretive consulting services to
help clarify strategic goals and key performance indicators (KPIs),
evolve financial processes, and enhance operational effectiveness.
To learn more about how G2G Ventures is a growth partner for
enduring business, connect with our team.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
pending litigation and other matters. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including, among other things: our history of
operating losses and uncertainty of future profitability; the final
outcome of any pending litigation; our ability to successfully
complete research and further development of our drug candidates;
the timing, cost and uncertainty of obtaining regulatory approvals
of our drug candidates; our ability to successfully commercialize
our drug candidates; dependence on royalties and grant revenue; our
ability to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230713154771/en/
Investor Relations Contact Navidea Biopharmaceuticals,
Inc. G2G Ventures - Executive Consultant Theodore Gerbick Chief
Marketing Officer tgerbick@g2g.ventures
Navidea Biopharmaceuticals (AMEX:NAVB)
過去 株価チャート
から 12 2024 まで 1 2025
Navidea Biopharmaceuticals (AMEX:NAVB)
過去 株価チャート
から 1 2024 まで 1 2025
